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Abstract	
Advanced diabetes technologies have produced increasingly favorable outcomes compared to older
treatments. Disparities in practice resources have led to a treatment disparity by clinical setting, where
endocrinologists typically prescribe far more such technologies than primary care providers (PCPs).
Fully automated artificial pancreas systems (APS), which combine technologies to deliver and adjust
insulin dosing continuously in response to automatic and continuous glucose monitoring, may be more
straightforward for PCPs to prescribe and manage, therefore extending their benefit to more patients.
We aimed to assess willingness of PCPs to prescribe advanced diabetes technologies through a
cross-sectional survey of PCPs from 4 geographically diverse centers. While respondents were
uncomfortable initiating (63 of 72, 88%) or adjusting (64 of 72, 89%) traditional insulin pumps, their
views on APS were quite different: 71 of 76 (93%) saw advantages to prescribing APS by PCPs rather
than only endocrinologists. Most would consider prescribing APS for type 1 diabetes (58 of 76, 76%)
and type 2 diabetes (52 of 76, 68%). No differences were seen among attendings, residents, or nurse
practitioners. APS were much more acceptable than traditional insulin pumps among this primary care
sample. If successful, primary care management of closed-loop APS would greatly increase access
to such therapies and reduce disparities among those patients who face more difficulty accessing
subspecialty care than they do primary care. (J Patient Cent Res Rev. 2021;8:272-276.)
Keywords	diabetes mellitus; primary care; endocrinology; continuous glucose monitoring; closed-loop systems;
technology; artificial pancreas

D

iabetes affects millions of people in the United
States; 32.6 million have type 2 diabetes (T2D),1
1.6 million have type 1 diabetes (T1D),1 and
gestational diabetes affects 6%–9% of pregnant women.2
From the point of diagnosis, every patient with T1D
requires daily injection of insulin, while patients with
T2D or gestational diabetes will usually begin insulin
therapy once lifestyle changes and oral medications
fail to provide optimal glucose control. Regardless,
patients with any type of diabetes will need to couple
their therapy regimen with multiple daily blood glucose
measurements, either through a standard glucometer or
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a subcutaneous continuous glucose monitor (CGM) in a
perpetual effort to compensate for the loss of physiologic
glycemic metabolism. To dose insulin, some people with
diabetes opt for using an insulin pump, programmed with
individually determined and time-specific basal rates,
correction factors, and insulin:carbohydrate ratios over
the more common multiple daily injections.3 Despite
multiple benefits,4,5 these insulin pumps are used by only
20%–30% of those with T1D and substantially fewer
with other forms of diabetes.6
Treatment of T1D, gestational diabetes, and many
cases of insulin-requiring T2D is completely, or nearly
completely, managed by the patients or their caregivers
themselves, requiring tremendous effort and leaving
plenty of room for human factors (eg, varying frequencies
of glucose checks, dosage adjustments, and carbohydrate
counting accuracy). Failure to navigate these factors can
lead to debilitating complications in both the short term,
such as severe hypoglycemia or diabetic ketoacidosis,
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or the long term, such as retinopathy, nephropathy,
neuropathy, or cardiovascular disease. Many patients
managed with insulin must meet with their diabetes care
providers to repeatedly adjust insulin dosing ratios and
rates to account for changes over time. Because of this,
and with advances in technology and computing, several
companies have pursued algorithms and technology to
automate insulin delivery. This includes the manufacturers
of the three most popular existing insulin pumps, who
are incorporating CGM technology into and adapting
their existing insulin pump products with incremental
automation features, resulting in so-called hybrid closedloop artificial pancreas systems (APS). These systems
provide varying degrees of automation and glycemic
improvement while still relying on user input and manual
determination of insulin dosing rates and ratios.7-10
Other examples currently in development — including
some in late-stage regulatory testing at the time of
this writing — employ fully closed-loop, completely
automated APS that mates CGM technology with newer
pumping technology and learning-control algorithms
to deliver rapid-acting insulin autonomously. One such
device only requires user input of weight and generates
the necessary basal rates, correction factors, and
insulin:carbohydrate ratios for the user. It is also designed
to adapt over time and adjust these ratios and rates to the
changing daily lifestyles of the user, without the need of
intervention from a trained physician, nurse practitioner,
physician assistant, or clinical pharmacist. In addition,
it does not require carbohydrate counting but gives the
user the ability for an optional meal bolus if they would
like to prime the device for better blood glucose control.
Prior studies have demonstrated that this automated
APS significantly decreases the substantial diabetes
self-management burden while improving glycemia,
thereby reducing time spent in both hypoglycemia and
hyperglycemia.11,12
Currently, diabetes technology like insulin pumps
and CGMs are prescribed more frequently by
endocrinologists.13,14 These devices are associated
with better outcomes4 but require special training and/
or office resources for providers to manage them for
their patients. Generally speaking, such training and
resources are available to most endocrinology practices
but to very few primary care practices. This disparity
in access exists despite CGM recommendations in the
American Diabetes Association’s current and prior
Standards of Medical Care in Diabetes.15,16 People with
T2D and gestational diabetes treated with insulin also
may be placed on insulin pumps in some circumstances
to tailor their insulin delivery as an alternative to
other treatments or to multiple daily insulin injections.
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These are usually managed by endocrinology, not
by primary care providers (PCPs),13,14 due to practice
resource and training differences. However, in contrast
to PCPs, endocrinologists are not broadly dispersed
geographically. A recent study found that more than 75%
of U.S. counties have no endocrinologists at all, while
96% of U.S. counties have at least one PCP, and while
all people live in or adjacent to a county with a PCP, the
nearest endocrinologist can be hundreds of miles and
many counties away.17
With emerging advanced artificial pancreas technology,
and especially fully automated closed-loop systems and
their ability to autonomously manage insulin dosing and
glycemia with only an initial input of the user’s weight, it
is quite likely that much of the advanced provider training
and extended practice resources may no longer be
necessary to support such systems. This is especially the
case for systems that can also autonomously determine
and perpetually update patient-specific ratios, correction
factors, and basal rates. As each person with diabetes has
a PCP within their own or neighboring county,17 having
advanced artificial pancreas technology prescribed by
PCPs would greatly increase the access to this important
technology beyond through endocrinologists alone,
addressing potential disparities deriving from lack of
access to endocrinologists. This would allow the benefits
of improved glycemia, including reduced time spent in
hyperglycemia and hypoglycemia, to reach not only more
patients but also more geographically distributed patients.
Before moving toward such a model, it is important
to assess provider perceptions and awareness of such
technologies. There is a paucity of literature on these
topics, some of which this study aimed to address by
investigating PCPs’ perceived barriers and willingness to
prescribe advanced diabetes technologies to patients with
T1D, T2D, and gestational diabetes.

METHODS

This cross-sectional study was approved by the Penn
State College of Medicine institutional review board.
Population

Eligible participants were PCPs, including physicians,
nurse practitioners, and physician assistants practicing
family medicine, general internal medicine, general
pediatrics, or obstetrics/gynecology. Targeted recruitment
was conducted through academic, residency, and health
system-based U.S. centers that responded to an email
inviting interest to participate. In turn, interested centers
sent an email announcement to their providers, with a link
to study information, including an explanation of the study
and opportunity to consent to participate. Participants
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could not continue to the survey unless they agreed that
they had read the summary and consent and would like to
participate. They were then presented with an eligibility
screener; if eligible based on the aforementioned criteria,
the survey followed immediately. Participants who
completed the survey could optionally enter a drawing
for one of two $100 electronic gift cards.
Measures

The instrument included questions about experience
with diabetes, advanced diabetes technology, patient
population, and provider demographics, including age,
gender, position, and specialty (Online Appendix A).
It was pilot tested prior to distribution among a group
of PCPs, who reviewed it for clarity and what they
perceived to be the meanings and intent of each item.
Minor adjustments to language were made based on pilot
results. After arriving at a final instrument, estimated
completion time among another sample of PCP testers
was 10–15 minutes. The survey and data were hosted
in REDCap,18,19 a secure electronic data collection
instrument supported by the Penn State Clinical and
Translational Science Institute.
Statistical Analyses

Descriptive statistics and inferential comparisons
were conducted with R software (The R Foundation).
Comparisons between groups employed 2-sided t-tests
for continuous items and chi-squared tests for categorical

items, at the 5% level of significance. To limit the number
of comparisons made, comparisons were predetermined
and made across groups where possible.

RESULTS

A total of 76 completed responses were obtained
from programs located in Connecticut, Hawaii, North
Carolina, and Pennsylvania. Due to the nature of survey
distribution, response rate could not be calculated.
Of 72 respondents who provided their position/role,
there were 45 (63%) attending physicians, 22 (31%)
residents, 4 (6%) nurse practitioners, and 1 (1%) clinical
pharmacist. Of 42 who provided their specialty, 22
(52%) reported family medicine, 10 (24%) obstetrics/
gynecology, 7 (17%) general pediatrics, and 3 (7%)
general internal medicine.
Respondents reported being uncomfortable initiating
(63 of 72, 88%) or adjusting (64 of 72, 89%) traditional
insulin pump therapy for patients with T2D. In all,
71 of 76 (93%) respondents — and 35 of 35 [100%]
respondents who shared their specialty and treated
adult patients — saw advantages to prescription of
APS by PCPs rather than only by subspecialists. Of 76
respondents, 58 (76%) PCPs would consider prescribing
APS for T1D, 52 (68%) would consider prescribing APS
for T2D, and 28 (37%) would consider prescribing APS
for gestational diabetes, with no differences between
attendings, residents, and nurse practitioners.

Table 1. Participant Responses Regarding APS Prescribing Beliefs and Intentions, by Position, Age, Years
Since Training, and Specialty

Participant characteristics

n

Position

45
22
4
32
36
21
23
28
7
3
22
10

Attending
Resident
Nurse practitioner
Age
< mean of 38 years
≥ mean of 38 years
Years
Still in training
since
0–10
training
10+
Medical General pediatrics
specialty General internal medicine
Family medicine
Obstetrics/Gynecology

Sees advantages
to PCP
Would consider
prescription of
ordering APS
APS devices
for T1D
Positive
Positive
response,
response,
n (%)
P
n (%)
P
40 (89)
22 (100)
4 (100)
28 (88)
35 (97)
21 (100)
20 (87)
26 (93)
2 (29)
3 (100)
22 (100)
10 (100)

0.333
0.180
0.263

<0.001

30 (67)
20 (91)
4 (100)
20 (63)
32 (89)
19 (91)
17 (74)
19 (68)
0 (0)
3 (100)
22 (100)
4 (40)

0.074
0.023
0.181

<0.001

Would consider
ordering APS
for T2D
Positive
response,
n (%)
P
28 (62)
18 (82)
4 (100)
17 (53)
30 (83)
17 (81)
17 (74)
16 (57)
0 (0)
3 (100)
20 (91)
3 (30)

0.072
0.015
0.172

<0.001

Would consider
ordering APS
for GD
Positive
response,
n (%)
P
16 (36)
9 (41)
2 (50)
8 (25)
16 (44)
8 (38)
11 (48)
8 (29)
0 (0)
2 (67)
6 (27)
4 (40)

0.862
0.155
0.368

0.121

APS, artificial pancreas system; GD, gestational diabetes; PCP, primary care provider; T1D, type 1 diabetes; T2D, type 2 diabetes.
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Those younger than the mean respondent age of 38 years
were less likely than those at or above the mean age to
consider prescribing APS for T1D (20 of 32 [63%] vs 32
of 36 [89%]; P=0.023) and T2D (17 of 32 [53%] vs 30 of
36 [83%]; P=0.015). There was no association between
time since training and willingness to prescribe APS
for either T1D or T2D. General pediatricians were not
willing to consider prescribing APS for T1D (P<0.001)
or T2D (P<0.001) and were less likely to see benefits of
PCPs prescribing APS (P<0.001) than their colleagues
in general internal medicine, family medicine, and
obstetrics/gynecology.
Additional results are detailed in Table 1.

DISCUSSION

While PCPs were overwhelmingly uncomfortable
initiating or adjusting traditional insulin pumps, they
largely agreed that there are advantages to prescribing
automated APS through primary care rather than only
through specialists. PCPs were generally willing to
consider prescribing automated APS for T1D and T2D
but not for gestational diabetes. When considering only
PCPs who treat adult patients, this willingness was even
more evident. Respondents with greater familiarity
with CGM were more likely to report advantages of
prescribing APS through primary care and to consider
doing so. However, a significant majority of even
those unfamiliar with CGM saw advantages and would
consider prescribing APS. Automated APS appear to
be much more acceptable to this sample of PCPs than
traditional insulin pumps.
The finding that younger respondents were less likely to
consider prescribing APS while no association was found
between time since training and willingness to prescribe
APS seems counterintuitive. This might be explained
on the basis of the differences in the comparisons — 2
groups (above or below the median) compared by age
versus 3 groups (with fewer in each group) compared
by years from training — making it less likely to find
a significant difference among the smaller years from
training groups.
If these results are true more generally, PCP receptivity
to using APS could increase access to greater numbers
of patients with diabetes. Distance from the nearest
endocrinologist would not need to be a limiting factor in
determining which patients with diabetes can have access
to the newest and most effective technology to manage
their disease. In the case of patients with gestational
diabetes, the effect of diabetes on pregnancy could be
lightened by giving an obstetrician the option to place
their patient on closed-loop APS for the duration of their
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disease, but more education must be provided to help
clear up misconceptions clearly seen in this study that
PCPs currently have against this emerging technology in
gestational diabetes.
Study limitations include the relatively small number of
respondents, in addition to underrepresentation of general
internal medicine and pediatrics, and the unexplained
finding that just 55% of respondents reported their
specialty, limiting generalizability. The survey described
the hypothetical diabetes management system based on
the known evidence and did not speculate or inquire about
potential PCP management or liability responsibilities.
While this approach kept focus on the facts, omission of
hypothetical impact on clinical practice may have influenced
survey responses. Another concern may be that including in
the survey instrument a description of a closed-loop APS
could have influenced respondents to report favorably about
it. While there is no way to refute this, it may be helpful to
consider that pediatrician respondents were not influenced
in this way, remaining unwilling to consider prescribing
such a system. We leave to the reader how to interpret
this when observing that family medicine and internal
medicine respondents were so likely to consider prescribing
closed-loop APS. Finally, the observational design makes
it impossible to evaluate directionality of associations;
clinical trials would overcome this.
Future trials should assess outcomes in artificial pancreas
system prescription and management by primary care
providers compared to endocrinologists. If successful,
primary care management of such advanced diabetes
technologies would greatly increase access to automated
therapies and reduce disparities among those who have a
harder time (if able to at all) accessing subspecialty care
than they do primary care.
Patient-Friendly Recap
• Primary care providers (PCPs) frequently treat patients
with diabetes; however, it is reported that PCPs do
not order traditional insulin pumps as frequently as
diabetes specialists, aka endocrinologists.
• Newer artificial pancreas systems that automate the
dosing of insulin have been shown to safely control
blood glucose levels.
• 76 PCPs practicing in 4 geographically different U.S.
states completed surveys regarding their comfort
level in prescribing automated technologies.
• Most PCPs surveyed reported they would consider
ordering artificial pancreas systems for type 1 and
type 2 diabetes but were resistant to do so for
gestational diabetes or for pediatric patients.
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